Docetaxel

ATC CODE

  • L01CD02

INDICATIONS AND NEMLC RECOMMENDATIONS

INDICATIONS AND NEMLC RECOMMENDATIONS 1

INDICATION

  • Squamous cell carcinoma of head and neck

NEMLC RECOMMENDATION

  • Approved
    Approved for patients with good performance status and adequate follow-up used in combination with cisplatin plus 5-fluoro-uracil.

REVIEW INDICATORS

  • None

DATE RATIFIED

  • 25 July 2013


INDICATIONS AND NEMLC RECOMMENDATIONS 2

INDICATION

  • Second-line therapy for advanced non-small cell lung cancer (NSCLC) in selected patients with good performance status (ECOG 0;1).

NEMLC RECOMMENDATION

  • Approved

REVIEW INDICATORS

  • None

DATE RATIFIED

  • 22 January 2015

INDICATIONS AND NEMLC RECOMMENDATIONS 3

INDICATION

Castrate resistant prostate cancer.

NEMLC RECOMMENDATION

  • Approved
    • Allow the use of combination chemotherapy with paclitaxel for patients who are:
      • Newly diagnosed with metastatic diasease
      • Patients who are > 12 months from primary chemoradiation prior to relapse/distant disease.
      • Note - Patients with GFR <30ml/min are not suitable for any platinum-based chemotherapy
      • Performance status <0,
      • No previous cisplatin.

REVIEW INDICATORS

  • Reduction in cost and availability of 3rd generation ARBs e.g. enzalutamide and CYP17 inhibitors e.g. abiraterone

DATE RATIFIED

  • 11 July 2019

INDICATIONS AND NEMLC RECOMMENDATIONS 4

INDICATION

  • Patients with hormone sensitive prostate cancer (HSPC).

NEMLC RECOMMENDATION

  • Approved
    • For patients with high volume disease: defined as the presence of visceral metastases or ≥4 bone lesions with ≥1 beyond the vertebral bodies and pelvis

REVIEW INDICATORS

  • New evidence

DATE RATIFIED

  • 30 January 2020